Alemtuzumab by Continuous Intravenous Infusion Followed by Subcutaneous Injection Plus Rituximab in the Treatment of Patients With Chronic Lymphocytic Leukemia Recurrence

BACKGROUND: Monoclonal antibodies may be used more effectively in combination. A previous study of intravenous (iv) bolus alemtuzumab plus rituximab in patients with chronic lymphocytic leukemia (CLL) recurrence produced a response rate of 54% after a 4-week treatment period. METHODS: To optimize do...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer
Hlavní autoři: Faderl, Stefan, Ferrajoli, Alessandra, Wierda, William, O'Brien, Susan, Lerner, Susan, Keating, Michael J.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2010
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4476388/
https://ncbi.nlm.nih.gov/pubmed/20225334
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.24958
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky